Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study-Reference-Cited by-同舟云学术

Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study

Published:2022-04-28 Issue:3 Volume:24 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Yoshida Kenta^ORCID,Chan Phyllis,Marchand Mathilde,Zhang Rong,Wu Benjamin,Ballinger Marcus,Sternheim Nitzan,Jin Jin Y.,Bruno René

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

https://link.springer.com/content/pdf/10.1208/s12248-022-00710-4.pdf

Reference15 articles.

1. Al-Huniti N, Feng Y, Yu JJ, Lu Z, Nagase M, Zhou D, et al. Tumor growth dynamic modeling in oncology drug development and regulatory approval: past, present, and future opportunities. CPT Pharmacometrics Syst Pharmacol. 2020;9(8):419–27. https://doi.org/10.1002/psp4.12542.

2. Bruno R, Bottino D, de Alwis DP, Fojo AT, Guedj J, Liu C, et al. Progress and opportunities to advance clinical cancer therapeutics using tumor dynamic models. Clin Cancer Res. 2020;26(8):1787–95. https://doi.org/10.1158/1078-0432.CCR-19-0287.

3. Yin A, Moes D, van Hasselt JGC, Swen JJ, Guchelaar HJ. A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors. CPT Pharmacometrics Syst Pharmacol. 2019;8(10):720–37. https://doi.org/10.1002/psp4.12450.

4. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res. 2011;17(4):907–17. https://doi.org/10.1158/1078-0432.CCR-10-1762.

5. Claret L, Jin JY, Ferte C, Winter H, Girish S, Stroh M, et al. A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non-small cell lung cancer based on early tumor kinetics. Clin Cancer Res. 2018;24(14):3292–8. https://doi.org/10.1158/1078-0432.CCR-17-3662.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer;European Journal of Cancer;2024-08

2. Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL;JTO Clinical and Research Reports;2024-07

3. Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches;CPT: Pharmacometrics & Systems Pharmacology;2024-04-17

4. Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302;CPT: Pharmacometrics & Systems Pharmacology;2023-12-21

5. Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics;Clinical Pharmacology & Therapeutics;2023-12-18